Hypoxia‐induced CXC chemokine ligand 14 expression drives protumorigenic effects through activation of insulin‐like growth factor‐1 receptor signaling in glioblastoma
Authors:
Open Access
- 1 October 2022
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 114 (1) , 174-186
Abstract
Hypoxic tumor microenvironment (HTM) promotes a more aggressive and malignant state in glioblastoma. However, little is known about the role and mechanism of CXC chemokine ligand 14 (CXCL14) in HTM-mediated glioblastoma progression. In this study, we report that CXCL14 expression correlated with poor outcomes, tumor grade, and hypoxia-inducible factor (HIF) expression in patients with glioblastoma. CXCL14 was upregulated in tumor cells within the hypoxic areas of glioblastoma. Hypoxia induced HIF-dependent expression of CXCL14, which promoted glioblastoma tumorigenicity and invasiveness in vitro and in vivo. Moreover, CXCL14 gain-of-function in glioblastoma cells activated insulin-like growth factor-1 receptor (IGF-1R) signal transduction to regulate the growth, invasiveness, and neurosphere formation of glioblastoma. Finally, systemic delivery of CXCL14 siRNA nanoparticles (NPs) with polysorbate 80 coating significantly suppressed tumor growth in vivo and extended the survival time in patient-derived glioblastoma xenografts. Together, these findings suggest that HIF-dependent CXCL14 expression contributes to HTM-promoted glioblastoma tumorigenicity and invasiveness through activation of the IGF-1R signaling pathway. CXCL14 siRNA NPs as an oligonucleotide drug can inhibit glioblastoma progression and constitute a translational path for the clinical treatment of glioblastoma patients.Keywords
This publication has 28 references indexed in Scilit:
- Cancer-Associated Fibroblasts Expressing CXCL14 Rely upon NOS1-Derived Nitric Oxide Signaling for Their Tumor-Supporting PropertiesCancer Research, 2014
- CXCL14 is a natural inhibitor of the CXCL12–CXCR4 signaling axisFEBS Letters, 2013
- Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1Neuro-Oncology, 2012
- Pleiotropic functions of the CXC-type chemokine CXCL14 in mammalsThe Journal of Biochemistry, 2012
- NADPH Oxidase Subunit 4-Mediated Reactive Oxygen Species Contribute to Cycling Hypoxia-Promoted Tumor Progression in Glioblastoma MultiformePLOS ONE, 2011
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009
- CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growthProceedings of the National Academy of Sciences, 2009
- IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I ReceptorClinical Cancer Research, 2007
- The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying TreatmentsClinical Oncology, 2007
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004